Professor Gert Ossenkoppele was appointed in 2003 as professor of Hematology at the VU University Medical Center in Amsterdam. Gert Ossenkoppele has authored over 390 publications in peer-reviewed journals and is an invited speaker at many international scientific meetings. His research interests are mainly translational and include the (stem cell) biology of AML, leukemic stem cell target discovery, immunotherapy, and measurable residual disease (MRD) detection using flow cytometry to inform treatment of AML. He is the PI of various clinical trials in myeloid malignancies. He chairs the AML working par
ty of HOVON (Dutch-Belgian Hematology Trial Group) and is appointed as vice-chair of the HOVON Executive Board. He is a lead participant of the AML Work package of the Europe...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Interview with EHA President Prof. Pieter Sonneveld Next Article
Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia »
Table of Contents: EHA 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.